A study assessing the responses of colorectal cancer (CRC) to capecitabine and oxaliplatin regimen found that those with ABCB1 gene variants (rs1128503 and rs1045642) had better disease-free survival rate (DFSR) and overall survival rate (OSR) [52]. Here, ABCB1 is linked to colorectal cancer.